New CurQD Research Makes Waves at USA’s Largest GI Conference

The DDW Conference: 

Digestive Disease Week (DDW) 2025—North America’s premier gastroenterology conference—brought together the world’s leading minds in digestive disease research, clinical care, and innovation. From May 3rd to 6th in San Diego, the event served as a global stage for breakthroughs in GI medicine, where science meets real-world solutions.

This year, Evinature made a powerful entrance. Our co-founders joined forces with globally recognized medical institutions and top-tier researchers to present cutting-edge data on the CurQD® Protocol. Far more than a nutraceutical, CurQD® was showcased as a clinically validated, cost-effective option for IBD patients—and a viable solution to today’s insurance and accessibility hurdles.

Poster 1: Cost-Effectiveness of CurQD® for Ulcerative Colitis

A recent study co-conducted by Professor Henit Yanai (Rabin Medical Center, Israel) and Dr. David Rubin (University of Chicago) investigated the cost-benefit analysis of using CurQD® to treat ulcerative colitis, both as an additive to existing treatment and on its own. This study determined that CurQD®, as a nutraceutical novel therapy, was a fraction of the cost of advanced therapies that have already received FDA-approval. The best part: CurQD® doesn’t even need to be FDA approved in order to reach patients, while maintaining the highest quality third-party testing available to market. 

Poster 2: Retrospective Crohn’s Disease Study 

In a presentation that was given earlier this year, Co-Founders Nir Salomon and Professor Shomron Ben-Horin displayed a clinical study wherein mild-to-moderate Crohn’s Disease patients took CurQD® and were monitored before, during and after treatment induction, with results testifying to the restorative potential of CurQD® in such medical cases. This presentation made a round at DDW this year as well, with high levels of success not seen in classic Crohn’s Disease studies or treatments until now. These findings confirm that CurQD® is effective not only for induction of remission in Crohn’s disease but also for maintenance, with real-world durability and low side-effect incidence.

Photo credit: Aaron Blocker, Instagram IBD Patient Advocate and Warrior (@aaronblocker_)

Behind the Scenes: 

Conferences aren’t just a crossroads for researchers, but the businessmen who put their money where their mouth is to invest real, science-backed solutions. DDW provided a tangible space for our Co-Founders to meet and hold productive conversations with high-ranking pharma reps, prominent gastroenterology science leaders and GI groups. These engagements reinforced CurQD®’s growing reputation as a clinically proven, economically viable nutraceutical protocol for IBD treatment while showing off its cost-benefit potential to help patients save and make gut healthcare affordable. 

Looking Ahead: 

Our presence at DDW 2025 marks a pivotal moment in Evinature’s journey—underscoring our commitment to scientific excellence and our mission to deliver accessible, effective treatments for patients with Ulcerative Colitis and Crohn’s Disease.

Stay tuned for further updates as we continue to expand CurQD®’s reach through clinical partnerships and global recognition.

Summer Pitocchelli-Schwartzman

Share